| Title |
Recent advances in the molecular understanding of glioblastoma
|
|---|---|
| Published in |
Journal of Neuro-Oncology, January 2012
|
| DOI | 10.1007/s11060-011-0793-0 |
| Pubmed ID | |
| Authors |
Fonnet E. Bleeker, Remco J. Molenaar, Sieger Leenstra |
| Abstract |
Glioblastoma is the most common and most aggressive primary brain tumor. Despite maximum treatment, patients only have a median survival time of 15 months, because of the tumor's resistance to current therapeutic approaches. Thus far, methylation of the O (6)-methylguanine-DNA methyltransferase (MGMT) promoter has been the only confirmed molecular predictive factor in glioblastoma. Novel "genome-wide" techniques have identified additional important molecular alterations as mutations in isocitrate dehydrogenase 1 (IDH1) and its prognostic importance. This review summarizes findings and techniques of genetic, epigenetic, transcriptional, and proteomic studies of glioblastoma. It provides the clinician with an up-to-date overview of current identified molecular alterations that should ultimately lead to new therapeutic targets and more individualized treatment approaches in glioblastoma. |
Mendeley readers
The data shown below were compiled from readership statistics for 563 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | <1% |
| Brazil | 2 | <1% |
| Germany | 1 | <1% |
| Finland | 1 | <1% |
| United Kingdom | 1 | <1% |
| Netherlands | 1 | <1% |
| Denmark | 1 | <1% |
| Belgium | 1 | <1% |
| Spain | 1 | <1% |
| Other | 1 | <1% |
| Unknown | 549 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 126 | 22% |
| Student > Master | 98 | 17% |
| Student > Ph. D. Student | 74 | 13% |
| Researcher | 54 | 10% |
| Student > Doctoral Student | 32 | 6% |
| Other | 70 | 12% |
| Unknown | 109 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 118 | 21% |
| Agricultural and Biological Sciences | 94 | 17% |
| Biochemistry, Genetics and Molecular Biology | 88 | 16% |
| Neuroscience | 28 | 5% |
| Chemistry | 28 | 5% |
| Other | 82 | 15% |
| Unknown | 125 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2023.
All research outputs
#1,021,572
of 23,342,092 outputs
Outputs from Journal of Neuro-Oncology
#33
of 3,020 outputs
Outputs of similar age
#6,907
of 248,742 outputs
Outputs of similar age from Journal of Neuro-Oncology
#1
of 19 outputs
Altmetric has tracked 23,342,092 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,020 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 248,742 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.